InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,313.71
(
0.11%
)
US TECH 100
18,186.80
(
-0.05%
)
Dow Jones
39,870.09
(
0.16%
)
Brent Oil
82.96
(
-0.69%
)
Bitcoin
70,238.08
(
-1.68%
)
Post# of 14684
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Solar_Express

Send PM Follow Ignore
Followers 73
Posts 10908
Boards Moderated 1
Alias Born 10/02/2009

Solar_Express

Re: None

Tuesday, 03/10/2020 7:11:10 AM

Tuesday, March 10, 2020 7:11:10 AM

Post# of 14684
NuGenerex Immuno-Oncology (formerly Antigen Express), a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD-4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) is being spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. Current S1 Filing for the NASDAQ
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up